Nuvation Bio Inc Financials
This page shows Nuvation Bio Inc (NUVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Nuvation Bio Inc has an operating margin of -338.7%, meaning the company retains $-339 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -7527.3% the prior year.
Nuvation Bio Inc's revenue surged 699.0% year-over-year to $62.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Nuvation Bio Inc carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.95, Nuvation Bio Inc holds $6.95 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Nuvation Bio Inc generates a -66.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -122.5% the prior year.
Nuvation Bio Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Nuvation Bio Inc generates $0.85 in operating cash flow (-$173.4M OCF vs -$204.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Nuvation Bio Inc earns $-15.6 in operating income for every $1 of interest expense (-$213.1M vs $13.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Nuvation Bio Inc generated $62.9M in revenue in fiscal year 2025. This represents an increase of 699.0% from the prior year.
Nuvation Bio Inc's EBITDA was -$211.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 64.3% from the prior year.
Nuvation Bio Inc reported -$204.6M in net income in fiscal year 2025. This represents an increase of 64.0% from the prior year.
Nuvation Bio Inc earned $-0.60 per diluted share (EPS) in fiscal year 2025. This represents an increase of 71.6% from the prior year.
Cash & Balance Sheet
Nuvation Bio Inc held $164.1M in cash against $47.2M in long-term debt as of fiscal year 2025.
Nuvation Bio Inc had 338M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Nuvation Bio Inc's operating margin was -338.7% in fiscal year 2025, reflecting core business profitability. This is up 7188.6 percentage points from the prior year.
Nuvation Bio Inc's net profit margin was -325.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6888.5 percentage points from the prior year.
Nuvation Bio Inc's ROE was -66.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 55.5 percentage points from the prior year.
Capital Allocation
Nuvation Bio Inc invested $115.1M in research and development in fiscal year 2025. This represents an increase of 16.1% from the prior year.
NUVB Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.9M+219.1% | $13.1M+171.5% | $4.8M+56.7% | $3.1M | N/A | $727K-49.3% | $1.4M | $0 |
| Cost of Revenue | N/A | $3.3M+30.0% | $2.6M+23.0% | $2.1M | N/A | $1.5M+12.5% | $1.3M | $0 |
| Gross Profit | N/A | $9.8M+332.9% | $2.3M+128.0% | $990K | N/A | -$788K-995.5% | $88K | $0 |
| R&D Expenses | $34.3M+18.9% | $28.8M+5.4% | $27.4M+11.2% | $24.6M | N/A | $27.7M-5.2% | $29.2M+127.7% | $12.8M |
| SG&A Expenses | $40.3M+7.9% | $37.4M-2.9% | $38.5M+8.7% | $35.4M | N/A | $19.6M+21.2% | $16.2M+119.6% | $7.4M |
| Operating Income | -$34.0M+39.7% | -$56.4M+11.3% | -$63.6M-7.8% | -$59.0M | N/A | -$48.1M+89.8% | -$470.4M-2228.8% | -$20.2M |
| Interest Expense | $8.1M+57.9% | $5.1M+1116.4% | $421K+679.6% | $54K | N/A | $120K-9.1% | $132K | $0 |
| Income Tax | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | -$36.6M+34.4% | -$55.8M+5.4% | -$59.0M-10.8% | -$53.2M | N/A | -$41.2M+91.1% | -$462.5M-3026.6% | -$14.8M |
| EPS (Diluted) | N/A | $-0.16+5.9% | $-0.17-6.3% | $-0.16 | N/A | $-0.15+92.1% | $-1.89-2600.0% | $-0.07 |
NUVB Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $594.8M-1.1% | $601.6M-7.1% | $647.2M+31.4% | $492.5M-8.9% | $540.6M-5.4% | $571.6M-3.9% | $594.8M-3.0% | $613.1M |
| Current Assets | $571.5M-1.0% | $577.5M-7.3% | $623.2M+31.0% | $475.6M-9.6% | $526.3M-6.9% | $565.0M-3.8% | $587.2M-3.4% | $608.1M |
| Cash & Equivalents | $164.1M+65.9% | $98.9M-60.1% | $248.0M+416.9% | $48.0M+34.3% | $35.7M+18.9% | $30.0M-12.4% | $34.3M-0.7% | $34.5M |
| Inventory | $11.4M+99.8% | $5.7M+934.4% | $552K+3842.9% | $14K | $0 | N/A | N/A | N/A |
| Accounts Receivable | $16.1M+93.2% | $8.3M+209.1% | $2.7M+558.4% | $409K-96.8% | $12.7M+11258.9% | $112K-4.3% | $117K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $289.1M+4.9% | $275.7M+0.5% | $274.3M+275.6% | $73.0M-5.0% | $76.8M+11.6% | $68.9M-79.6% | $337.6M+1669.1% | $19.1M |
| Current Liabilities | $82.2M+20.7% | $68.1M+2.7% | $66.4M+25.7% | $52.8M-9.4% | $58.2M-1.3% | $59.0M+15.5% | $51.1M+224.2% | $15.8M |
| Long-Term Debt | $47.2M+0.3% | $47.1M+0.2% | $47.0M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $305.7M-6.2% | $325.9M-12.6% | $372.9M-11.1% | $419.5M-9.6% | $463.8M-7.7% | $502.7M+95.5% | $257.2M-56.7% | $594.0M |
| Retained Earnings | -$1.1B-3.4% | -$1.1B-5.5% | -$1.0B-6.1% | -$964.0M-5.8% | -$910.7M-5.7% | -$861.3M-5.0% | -$820.1M-129.3% | -$357.6M |
NUVB Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.7M+43.8% | -$52.9M-9.8% | -$48.2M-13.0% | -$42.6M+7.9% | -$46.3M-49.0% | -$31.1M+16.7% | -$37.3M-137.7% | -$15.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $87.1M+190.1% | -$96.6M-276.1% | $54.9M+1.3% | $54.2M+4.7% | $51.8M+77.8% | $29.1M-15.0% | $34.3M+354.4% | $7.5M |
| Financing Cash Flow | $8.1M+1509.4% | $501K-99.7% | $193.4M+35196.2% | $548K+160.9% | -$900K+41.5% | -$1.5M-156.0% | $2.7M+12985.7% | $21K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NUVB Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 74.5%+27.8pp | 46.7%+14.6pp | 32.1% | N/A | -108.4%-114.5pp | 6.1% | N/A |
| Operating Margin | -81.3%+348.8pp | -430.1%+885.6pp | -1315.7%+597.5pp | -1913.2% | N/A | -6616.4%+26163.1pp | -32779.4% | N/A |
| Net Margin | -87.4%+337.8pp | -425.2%+795.7pp | -1220.9%+505.3pp | -1726.2% | N/A | -5668.5%+26560.9pp | -32229.4% | N/A |
| Return on Equity | -12.0%+5.1pp | -17.1%-1.3pp | -15.8%-3.1pp | -12.7% | N/A | -8.2%+171.6pp | -179.8%-177.3pp | -2.5% |
| Return on Assets | -6.2%+3.1pp | -9.3%-0.2pp | -9.1%+1.7pp | -10.8% | N/A | -7.2%+70.5pp | -77.8%-75.3pp | -2.4% |
| Current Ratio | 6.95-1.5 | 8.48-0.9 | 9.39+0.4 | 9.01-0.0 | 9.04-0.5 | 9.57-1.9 | 11.49-27.1 | 38.58 |
| Debt-to-Equity | 0.150.0 | 0.14+0.0 | 0.13-0.0 | 0.170.0 | 0.17+0.0 | 0.14-1.2 | 1.31+1.3 | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Nuvation Bio Inc's annual revenue?
Nuvation Bio Inc (NUVB) reported $62.9M in total revenue for fiscal year 2025. This represents a 699.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nuvation Bio Inc's revenue growing?
Nuvation Bio Inc (NUVB) revenue grew by 699% year-over-year, from $7.9M to $62.9M in fiscal year 2025.
Is Nuvation Bio Inc profitable?
No, Nuvation Bio Inc (NUVB) reported a net income of -$204.6M in fiscal year 2025, with a net profit margin of -325.3%.
What is Nuvation Bio Inc's EBITDA?
Nuvation Bio Inc (NUVB) had EBITDA of -$211.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Nuvation Bio Inc have?
As of fiscal year 2025, Nuvation Bio Inc (NUVB) had $164.1M in cash and equivalents against $47.2M in long-term debt.
What is Nuvation Bio Inc's operating margin?
Nuvation Bio Inc (NUVB) had an operating margin of -338.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nuvation Bio Inc's net profit margin?
Nuvation Bio Inc (NUVB) had a net profit margin of -325.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nuvation Bio Inc's return on equity (ROE)?
Nuvation Bio Inc (NUVB) has a return on equity of -66.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nuvation Bio Inc's operating cash flow?
Nuvation Bio Inc (NUVB) generated -$173.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nuvation Bio Inc's total assets?
Nuvation Bio Inc (NUVB) had $594.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Nuvation Bio Inc spend on research and development?
Nuvation Bio Inc (NUVB) invested $115.1M in research and development during fiscal year 2025.
What is Nuvation Bio Inc's current ratio?
Nuvation Bio Inc (NUVB) had a current ratio of 6.95 as of fiscal year 2025, which is generally considered healthy.
What is Nuvation Bio Inc's debt-to-equity ratio?
Nuvation Bio Inc (NUVB) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nuvation Bio Inc's return on assets (ROA)?
Nuvation Bio Inc (NUVB) had a return on assets of -34.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nuvation Bio Inc's cash runway?
Based on fiscal year 2025 data, Nuvation Bio Inc (NUVB) had $164.1M in cash against an annual operating cash burn of $173.4M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nuvation Bio Inc's Piotroski F-Score?
Nuvation Bio Inc (NUVB) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nuvation Bio Inc's earnings high quality?
Nuvation Bio Inc (NUVB) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nuvation Bio Inc cover its interest payments?
Nuvation Bio Inc (NUVB) has an interest coverage ratio of -15.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nuvation Bio Inc?
Nuvation Bio Inc (NUVB) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.